Psoriatic Immune Response to Tildrakizumab

ConditionPsoriasis Vulgaris

Trial statusRecruiting

Trial phasePhase 4

Trial typeInterventional

Biological sexAll

Age18-75

SponsorUniversity of California, San Francisco

About this trial

This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the IL23 blocker, tildrakizumab.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

18 years of age or older

Patients with moderate-severe psoriasis or > 5% body surface area affected.

Disqualifiers

taking systemic immunosuppressives in the last 4 weeks

pregnancy

severe immunodeficiency (either from genetic or infectious causes).

tuberculosis or other active serious infection

Trial design

Design model

Single group

Treatments tested in this trial

Tildrakizumab Prefilled Syringe
Drug
IL-23 inhibitor

Treatment groups

10 Participants

are divided into 1 treatment group

Group A: Tildrakizumab treatmentExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

Change in Psoriasis Area and Severity Index (PASI) Score at baseline and 3 months of treatment

Change in severity and extent of psoriasis (calculated by Psoriasis Area and Severity Index (PASI) score); scale range of 0 to 72, 72 being maximal disease.

Time frame

Baseline, 3 months

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University of California, San Francisco

Lead sponsor

Sun Pharmaceutical Industries Limited

Collaborator

Source ClinicalTrials.gov

Apply now